前言

2026年美国癌症研究协会（AACR）年会于4月17日至22日在美国圣地亚哥拉开帷幕。作为全球肿瘤领域最具影响力的学术盛会之一，AACR年会始终是重磅创新药物和前沿基础研究的首发阵地。本届会议上，中国消化系统肿瘤领域的专家学者再次闪耀国际舞台，12项重磅研究成果成功入选口头报告。本文现对相关研究进行梳理汇总。

摘要号:CT086/17

A phase 1/2, first-in-human study of an ADC targeting CDH17 (DB-1324) in participants with advanced/metastatic gastrointestinal tumor

DB-1324（靶向CDH17的抗体药物偶联物）治疗晚期/转移性胃肠道肿瘤的I/II期首次人体研究    

讲者：沈琳北京大学肿瘤医院

摘要号:CT145/9

A phase II, multicenter, open-label study (COMPASSION-26) of cadonilimab, a PD-1/CTLA-4 bispecific antibody,combined with chemotherapy (chemo) as first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC)

COMPASSION-26研究：卡度尼利单抗（PD-1/CTLA-4双特异性抗体）联合化疗一线治疗晚期胰腺导管腺癌的II期、多中心、开放标签研究

讲者：Zhongmin Maxwell Wang 北京大学第三医院

摘要号:CT146/10

Sequential treatment with surufatinib combined with gemcitabine and nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG induction therapy: A two-cohort, exploratory phase II study

索凡替尼联合吉西他滨+白蛋白结合型紫杉醇（AG方案）或AG方案单药序贯治疗作为AG诱导治疗6周后的局部晚期或转移性胰腺导管腺癌（mPDAC）一线治疗：一项双队列、探索性II期研究

讲者：李佳林 复旦大学附属肿瘤医院

摘要号:CT150/14

Sintilimab plus cisplatin and nab-paclitaxel induction treatment for locally advanced borderline resectable esophageal squamous cell carcinoma: A single-arm, prospective, phase 2 study (NEOCRTEC2001)

信迪利单抗联合顺铂+白蛋白结合型紫杉醇诱导治疗局部晚期交界可切除食管鳞状细胞癌：一项单臂、前瞻性、II期研究（NEOCRTEC2001）

讲者：Xin Zhang 中山大学肿瘤防治中心

摘要号:CT151/15

CDK4/6 inhibitor dalpiciclib combined with mFOLFOX6 in pretreated metastatic colorectal cancer: Results from a Simon two-stage phase II study

CDK4/6抑制剂达尔西利联合mFOLFOX6方案治疗经治转移性结直肠癌：Simon两阶段II期研究结果

讲者：谢晓煜 中山大学附属第六医院

摘要号:CT152/16

Preliminary results from a phase II trial evaluating the safety and efficacy of JS207, a bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic colorectal cancer

JS207（靶向PD-1和VEGF的双特异性抗体）联合化疗治疗转移性结直肠癌的II期试验初步结果

讲者：高勇 上海市东方医院

摘要号:CT159/23

JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study

JS207（靶向PD-1和VEGF-A的双特异性抗体）联合JS007（抗CTLA-4抗体）治疗晚期肝细胞癌的随机、多中心、II期研究

讲者：周俭复旦大学附属中山医院

摘要号:CT160/24

Updated multicenter phase Ib/II analysis of surufatinib plus sintilimab and capecitabine in previously treated metastatic small bowel adenocarcinoma and appendiceal carcinoma

索凡替尼联合信迪利单抗及卡培他滨治疗经治转移性小肠腺癌和阑尾癌的多中心Ib/II期研究更新分析

讲者：谢晓煜 中山大学附属第六医院

摘要号:1315

Genomic signatures in red blood cell DNA enable early non-invasive detection of colorectal neoplasia: A multicenter clinical study

红细胞DNA基因组标志物实现结直肠肿瘤的早期无创检测：一项多中心临床研究

讲者：X. Yao 西湖大学

摘要号:6728

Predicting gastric cancer response to anti-PD-1 first-line treatment based on multi-modal data: A multi-center study

基于多模态数据预测胃癌抗PD-1一线治疗反应：一项多中心研究

讲者：J. Wang 复旦大学附属中山医院

摘要号:6769

Modeling of acquired resistance to the multi-RAS inhibitor RMC6236 in KRAS mutant pancreatic ductal adenocarcinoma

KRAS突变胰腺导管腺癌中对多RAS抑制剂RMC6236获得性耐药的建模研究

讲者：Di Zhan 上海睿智化学研究有限公司

摘要号:6779

Molecular glue degraders of the RNA binding protein HuR to treat BRAF-mutant colorectal cancer

靶向RNA结合蛋白HuR的分子胶降解剂治疗BRAF突变结直肠癌

讲者：Z. Yang 上海达歌生物医药科技有限公司